GeoVax Labs: Advancing Next Generation Vaccines and Immunotherapies

Market Focus

GeoVax Labs Inc (NASDAQ: GOVX) is a clinical stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. With global vaccine and immunotherapy markets projected to exceed 300 billion dollars by the end of the decade, GeoVax is addressing significant unmet needs among immunocompromised populations, cancer patients, and those at risk from emerging infectious threats. The company’s multi antigen vaccine design and proprietary viral vector technology position it as a differentiated player in the evolving landscape of global healthcare solutions.

Platform and Technology Strategy

At the core of GeoVax’s approach is its Modified Vaccinia Ankara (MVA) vector platform, which enables the development of vaccines expressing multiple antigens to induce durable and broad immune responses. This technology is being applied across infectious disease prevention and oncology immunotherapy.

Key programs include:

• GEO CM04S1 – A next generation COVID 19 vaccine encoding both spike (S) and nucleocapsid (N) proteins, designed to protect immunocompromised patients where mRNA vaccines have limitations.

• Gedeptin® – A novel cancer immunotherapy currently in Phase 1/2 studies for recurrent head and neck cancers, with potential expansion into additional solid tumors.

• GEO MVA – A Mpox and smallpox vaccine advancing under favorable regulatory guidance from the European Medicines Agency, with potential applications in pandemic preparedness.

  
  

This multi program strategy leverages GeoVax’s proprietary vector platform to create differentiated assets across high need therapeutic categories.

Recent Progress, Growth and Partnerships

GeoVax entered the second half of 2025 with positive clinical momentum. The company reported favorable Phase 2 trial results for GEO CM04S1 in patients with chronic lymphocytic leukemia, where the vaccine achieved its primary immune endpoint while the comparator mRNA vaccine did not. Enrollment has now continued exclusively in the GeoVax arm, validating its potential as a superior option for immunocompromised patients.

In oncology, Gedeptin completed enrollment in a multicenter Phase 1/2 trial, building a foundation for expanded studies and combination strategies. The company also advanced its GEO MVA vaccine program with regulatory feedback from the EMA, supporting a streamlined development path in Europe. Alongside these clinical milestones, GeoVax continues to expand its patent portfolio and collaborations with leading research institutions, enhancing both scientific and commercial positioning.

Partnerships, Funding and Strategic Positioning

GeoVax is executing a strategy that combines targeted fundraising, non dilutive funding opportunities, and partnerships with academic and government organizations. The company recently strengthened its financial position through equity offerings and grant support, while maintaining a disciplined approach to capital allocation. Collaborations with clinical research centers expand trial capabilities and validate its technology in both infectious disease and oncology settings.

By addressing underserved patient populations, particularly those for whom existing vaccines or treatments are inadequate, GeoVax is carving out a strategic niche with high barriers to entry and significant growth potential.

Leadership and Capital Markets Strategy

GeoVax is led by Chairman and CEO David Dodd, a veteran of the life sciences industry with decades of experience in vaccine development, global healthcare strategy, and public company leadership. He is supported by a team with deep expertise in virology, immunology, oncology, and clinical development. The company is publicly listed on NASDAQ under ticker GOVX, providing broad access to institutional and retail investors seeking exposure to innovative vaccine and immunotherapy platforms.

Near Term Catalysts

• Additional Phase 2 data readouts from GEO CM04S1 in immunocompromised and healthy populations

• Clinical updates from Gedeptin® in advanced head and neck cancer

• Advancement of GEO MVA vaccine program under EMA guidance and potential partnering discussions

• Expansion of collaborations and presentations at international scientific conferences

• Potential new intellectual property allowances strengthening the competitive moat

Conclusion

GeoVax Labs offers investors a compelling opportunity to participate in the development of next generation vaccines and immunotherapies. With differentiated technology, promising clinical data, expanding global partnerships, and a strengthened balance sheet, the company is strategically positioned to create long term value while addressing critical unmet needs in infectious disease prevention and cancer treatment.

Interested in Attending or Presenting?

🔹 Prospective Attendees: Click here to join our upcoming investor events and discover emerging opportunities across the resource, biotech, and technology sectors.

🔹 Companies Seeking Exposure: Click here to learn how to present at one of our curated investor showcases and connect with active family offices, funds, and high-net-worth investors.

For additional info or to schedule a call, feel free to reach out.

Jimmy Lederer

Vice President

Trinity Financing Investments Corporation

Phone: 347-514-0000

Email: jimmy@trinityfinancinginvestments.com

All content provided is for informational and educational purposes only and should not be construed as investment advice or an offer or solicitation in respect to any products or services. The content presented should not be used as the basis for any investment decision, and does not purport to provide any legal, tax or accounting advice. There are inherent risks involved with investing in Issuers, as set out in the public disclosure record of each Issuer. Issuers are not responsible for revising or updating any information that they present via TFIC events.

Investors should refer to the continuous disclosure documents filed by each Issuer under applicable securities laws, including risk factors and warnings regarding “forward looking information”. Issuers are solely responsible for compliance with applicable securities laws, and TFIC makes no representations and provides no assurances to Investors regarding the accuracy or truthfulness of information presented by Issuers via TFIC events or in their public disclosure records. 

TFIC does not recommend or endorse any Issuer that presents via TFIC events, nor does TFIC verify the accuracy of any information presented by Issuers to Investors via TFIC events or in their public disclosure records. TFIC’s sole responsibility as the operator of TFIC events is to provide a platform for Investors and Issuers to communicate directly.

ALL CONTENT PRESENTED BY ISSUER(S) IS PROVIDED BY THE ISSUER(S) "AS IS" AND “AS AVAILABLE”. TFIC DOES NOT GUARANTEE THE ACCURACY OF ITS CONTENT. BY ATTENDING, EACH INVESTOR AGREES TO ACCEPT ANY RISKS ASSOCIATED AND ACKNOWLEDGES THAT TFIC IS NOT RESPONSIBLE FOR ANY CONTENT PRESENTED BY OR RELATING TO ISSUERS ON THE PLATFORM. 

TFIC DOES NOT WARRANT THAT THE PROVISION OF INFORMATION BY ISSUERS IN THEIR PRESENTATION WILL BE ERROR-FREE, TIMELY, COMPLETE OR ACCURATE. ATTENDANCE AND RELIANCE ON INFORMATION RECIEVED THEREON IS AT INVESTOR’S SOLE RISK. TFIC WILL NOT BE IN ANY WAY BE LIABLE TO ANY INVESTOR OR ISSUER OR ANY OTHER ENTITY OR PERSON FOR ANY INACCURACIES, ERRORS, OMISSIONS, DELAYS, DAMAGES, CLAIMS, LIABILITIES OR LOSSES, REGARDLESS OF CAUSE, IN OR ARISING FROM THE USE OF THE PLATFORM.

IN NO EVENT WILL TFIC BE LIABLE FOR ANY DAMAGES, INCLUDING WITHOUT LIMITATION DIRECT OR INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, LOSSES OR EXPENSES ARISING IN CONNECTION WITH THE ATTENDANCE BY INVESTORS AND/OR ISSUERS EVEN IF TFIC IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, LOSSES OR EXPENSES. FURTHER, TFIC SHALL NOT BE LIABLE IN ANY MANNER FOR THE PRODUCT OR SERVICES OF ANYONE WHO REDISTRIBUTES THE INFORMATION PROVIDED ON THE PLATFORM, AND SUCH REDISTRIBUTION IS EXPRESSLY PROHIBITED.